| 0.6892 -0.017 (-2.37%) | 05-08 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.14 | 1-year : | 1.38 |
| Resists | First : | 0.98 | Second : | 1.19 |
| Pivot price | 0.89 |
|||
| Supports | First : | 0.64 | Second : | 0.54 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.9 |
| MA(100) : | 1.26 |
MA(250) : | 2.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 16.4 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 6.75 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SHPH ] has closed above bottom band by 10.8%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.72 - 0.72 | 0.72 - 0.72 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.68 - 0.69 | 0.69 - 0.7 |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Thu, 07 May 2026
Shuttle Pharmaceuticals Completes Merger and PIPE Financing - TipRanks
Thu, 07 May 2026
Ryan Trasolini named Co‑CEO of Shuttle as Oleh Nabyt resigns from board - TradingView
Thu, 07 May 2026
Shuttle Pharmaceuticals Closes United Dogecoin Merger and Secures $9.55M PIPE Financing - TradingView
Thu, 07 May 2026
Shuttle Pharma (NASDAQ: SHPH) closes United Dogecoin deal and $9.55M PIPE - Stock Titan
Fri, 01 May 2026
Shuttle Pharmaceuticals to Acquire United Dogecoin; Adds $11 Million PIPE and Amends Prior Deal - TradingView
Thu, 30 Apr 2026
Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner - TMX Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 71 (K) |
| Shares Short P.Month | 39 (K) |
| EPS | -7.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.8 % |
| Return on Equity (ttm) | -791.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |